<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/quanterix-corp-nasdaqqtrx-expected-to-post-quarterly-sales-of-14-18-million.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T15:48:41+00:00"/>
    <meta property="og:title" content="Quanterix Corp (NASDAQ:QTRX) Expected to Post Quarterly Sales of $14.18 Million"/>
    <meta property="og:description" content="Wall Street brokerages expect Quanterix Corp (NASDAQ:QTRX) to post sales of $14.18 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Quanterix’s earnings. The lowest sales estimate is $13.30 million and the highest is $15.15 million. Quanterix posted sales of $10.88 million in the same quarter last year, which would […]"/>
  </head>
  <body>
    <article>
      <h1>Quanterix Corp (NASDAQ:QTRX) Expected to Post Quarterly Sales of $14.18 Million</h1>
      <address><time datetime="2019-11-18T15:48:41+00:00">18 Nov 2019, 15:48</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/quanterix-corp-logo.jpg"/>
      </figure>
      <p>Wall Street brokerages expect Quanterix Corp (NASDAQ:QTRX) to post sales of $14.18 million for the current fiscal quarter, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks</a> reports. Three analysts have provided estimates for Quanterix’s earnings. The lowest sales estimate is $13.30 million and the highest is $15.15 million. Quanterix posted sales of $10.88 million in the same quarter last year, which would indicate a positive year over year growth rate of 30.3%. The firm is expected to announce its next quarterly earnings results on Monday, March 16th.</p>
      <p>On average, analysts expect that Quanterix will report full year sales of $54.96 million for the current financial year, with estimates ranging from $54.10 million to $55.87 million. For the next fiscal year, analysts forecast that the company will post sales of $70.85 million, with estimates ranging from $68.05 million to $74.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Quanterix.</p>
      <p>QTRX has been the topic of a number of recent analyst reports. BTIG Research set a $35.00 price target on shares of Quanterix and gave the stock a “buy” rating in a report on Wednesday, August 7th. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 target price on shares of Quanterix in a research note on Thursday, November 7th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=QTRX">ValuEngine</a> downgraded shares of Quanterix from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> raised shares of Quanterix from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Wednesday, October 9th.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/QTRX/earnings/">Quanterix stock</a> traded down $0.35 on Monday, reaching $22.60. The stock had a trading volume of 5,951 shares, compared to its average volume of 173,598. Quanterix has a 1 year low of $16.03 and a 1 year high of $36.15. The company has a market cap of $631.03 million, a P/E ratio of -15.87 and a beta of 1.25. The company has a current ratio of 7.61, a quick ratio of 4.91 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $21.56 and its two-hundred day moving average is $26.07.</p>
      <p>In other Quanterix news, SVP David C. Duffy sold 1,667 shares of Quanterix stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.68, for a total transaction of $42,808.56. Also, Director Marijn E. Dekkers sold 89,759 shares of Quanterix stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $13.63, for a total transaction of $1,223,415.17. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/1216068/000110465919046955/a4.xml">here</a>. Insiders sold 101,914 shares of company stock worth $1,508,882 over the last ninety days. 30.80% of the stock is currently owned by insiders.</p>
      <p>Several hedge funds have recently bought and sold shares of QTRX. Steward Partners Investment Advisory LLC purchased a new position in shares of Quanterix during the second quarter worth approximately $76,000. Parametric Portfolio Associates LLC purchased a new position in shares of Quanterix during the second quarter worth approximately $212,000. Royal Bank of Canada raised its stake in shares of Quanterix by 116.4% during the second quarter. Royal Bank of Canada now owns 6,285 shares of the company’s stock worth $213,000 after acquiring an additional 3,380 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Quanterix by 13.1% during the third quarter. Rhumbline Advisers now owns 12,721 shares of the company’s stock worth $279,000 after acquiring an additional 1,469 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Quanterix by 607.1% during the second quarter. Cubist Systematic Strategies LLC now owns 9,617 shares of the company’s stock worth $325,000 after acquiring an additional 8,257 shares in the last quarter. 57.84% of the stock is currently owned by hedge funds and other institutional investors.</p>
      <p>
        <b>Quanterix Company Profile</b>
      </p>
      <p>Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/what-is-quick-ratio/">What is the Quick Ratio?</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=QTRX">Get a free copy of the Zacks research report on Quanterix (QTRX)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=QTRX"/>
      </figure>
    </article>
  </body>
</html>